MY183605A - Triazine compound and use thereof for medical purposes - Google Patents

Triazine compound and use thereof for medical purposes

Info

Publication number
MY183605A
MY183605A MYPI2016703028A MYPI2016703028A MY183605A MY 183605 A MY183605 A MY 183605A MY PI2016703028 A MYPI2016703028 A MY PI2016703028A MY PI2016703028 A MYPI2016703028 A MY PI2016703028A MY 183605 A MY183605 A MY 183605A
Authority
MY
Malaysia
Prior art keywords
triazine compound
medical purposes
formula
compound
disease
Prior art date
Application number
MYPI2016703028A
Other languages
English (en)
Inventor
Hironobu Nagamori
Ikuo Mitani
Masaki Yamashita
Takahiro Hotta
Yuichi Nakagawa
Masatoshi Ueda
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of MY183605A publication Critical patent/MY183605A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/22—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI2016703028A 2014-02-20 2015-02-19 Triazine compound and use thereof for medical purposes MY183605A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014031035 2014-02-20
PCT/JP2015/054519 WO2015125842A1 (ja) 2014-02-20 2015-02-19 トリアジン化合物及びその医薬用途

Publications (1)

Publication Number Publication Date
MY183605A true MY183605A (en) 2021-03-02

Family

ID=53878341

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2016703028A MY183605A (en) 2014-02-20 2015-02-19 Triazine compound and use thereof for medical purposes

Country Status (32)

Country Link
US (3) US20150266834A1 (https=)
EP (2) EP3456713A1 (https=)
JP (4) JP6461637B2 (https=)
KR (1) KR102360699B1 (https=)
CN (1) CN106232585B (https=)
AR (1) AR099498A1 (https=)
AU (1) AU2015219920B2 (https=)
BR (1) BR112016018341B1 (https=)
CA (1) CA2936408C (https=)
CL (1) CL2016002091A1 (https=)
CY (1) CY1121261T1 (https=)
DK (1) DK3109240T3 (https=)
ES (1) ES2704922T3 (https=)
HR (1) HRP20182134T1 (https=)
IL (1) IL247319B (https=)
LT (1) LT3109240T (https=)
MX (1) MX369217B (https=)
MY (1) MY183605A (https=)
PE (2) PE20211548A1 (https=)
PH (1) PH12016501651B1 (https=)
PL (1) PL3109240T3 (https=)
PT (1) PT3109240T (https=)
RS (1) RS58235B1 (https=)
RU (1) RU2692789C2 (https=)
SA (1) SA516371701B1 (https=)
SG (1) SG11201606902QA (https=)
SI (1) SI3109240T1 (https=)
SM (1) SMT201800684T1 (https=)
TR (1) TR201821158T4 (https=)
TW (1) TWI651310B (https=)
WO (1) WO2015125842A1 (https=)
ZA (1) ZA201606449B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI651310B (zh) * 2014-02-20 2019-02-21 日商日本煙草產業股份有限公司 三化合物及其醫藥用途
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
WO2016101885A1 (en) * 2014-12-24 2016-06-30 National Institute Of Biological Sciences, Beijing Necrosis inhibitors
JP6478255B2 (ja) * 2015-03-04 2019-03-06 株式会社島津製作所 蛍光誘導体化試薬及びアミン分析方法
KR20180037270A (ko) * 2015-08-17 2018-04-11 니뽄 다바코 산교 가부시키가이샤 히드록시트리아진 화합물 및 그의 의약 용도
EP3372589B1 (en) * 2015-10-29 2021-10-20 ASKA Pharmaceutical Co., Ltd. Pyrimidine derivative
GB201603311D0 (en) * 2016-02-25 2016-04-13 Jakobsson Per Johan New uses and methods
WO2018026798A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda modulators and methods of using same
JP7036792B2 (ja) * 2016-08-01 2022-03-15 アプティニックス インコーポレイテッド スピロ－ラクタムｎｍｄａ受容体修飾因子およびその使用
WO2019002183A1 (de) * 2017-06-26 2019-01-03 Merck Patent Gmbh Verfahren zur herstellung substituierter stickstoffhaltiger heterocyclen
CN114502163A (zh) * 2019-07-22 2022-05-13 安吉昂生物医药公司 作为rho相关卷曲螺旋激酶(rock)抑制剂的乙炔基杂环
US11786538B2 (en) * 2019-12-11 2023-10-17 Somerset Therapeutics, Llc Low benzalkonium chloride bimatoprost ophthalmic compositions with effective penetration and preservation properties
KR102157466B1 (ko) * 2020-05-19 2020-09-17 동아대학교 산학협력단 헥사하이드로트리아진 유도체를 포함하는 방광암의 예방, 개선 또는 치료용 조성물
KR20230142739A (ko) 2021-02-02 2023-10-11 아스카 세이야쿠 가부시키가이샤 피리미딘 유도체
TW202409037A (zh) 2022-07-06 2024-03-01 日商Ａｓｋａ製藥股份有限公司 嘧啶衍生物

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH473818A (de) 1964-03-18 1969-06-15 Ciba Geigy Verfahren zur Herstellung von neuen Hydroxyphenyl-1,3,5-triazinen und deren Verwendung
EP0051067A1 (en) * 1980-04-22 1982-05-12 Commonwealth Scientific And Industrial Research Organisation Triazine synthesis
SU1313854A1 (ru) 1985-04-17 1987-05-30 Институт Органической Химии Ан Армсср Способ получени смеси 2-оксо-2,3-дигидро-4,6,-бис-(3 @ -диэтиламинометилен-4 @ -оксифенил)-1,3,5-триазина и 2,4,6-трис-(3 @ -диэтиламинометилен-4 @ -оксифенил)-1,3,5-триазина
DE19543730A1 (de) * 1995-11-23 1997-05-28 Ciba Geigy Ag Bis-Resorcinyl-Triazine
US6096753A (en) 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
TW520362B (en) 1996-12-05 2003-02-11 Amgen Inc Substituted pyrimidine compounds and pharmaceutical composition comprising same
AU733877C (en) * 1996-12-05 2003-05-08 Amgen, Inc. Substituted pyrimidine compounds and their use
ZA9710727B (en) 1996-12-05 1998-06-12 Amgen Inc Substituted pyrimidine compounds and methods of use.
US6410729B1 (en) 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
GB9726987D0 (en) 1997-12-22 1998-02-18 Glaxo Group Ltd Compounds
PL350884A1 (en) 1999-04-01 2003-02-10 Pfizer Prod Inc Aminopyrimidines as sorbitol dehydrogenase inhibitors
US20040082627A1 (en) * 2002-06-21 2004-04-29 Darrow James W. Certain aromatic monocycles as kinase modulators
WO2008124092A2 (en) 2007-04-03 2008-10-16 E. I. Du Pont De Nemours And Company Substituted benzene fungicides
BR122017025417B1 (pt) 2008-06-04 2018-09-04 Adeka Corp Método para produção do composto 2,4,6-tri (hidroxifenil)-1,3,5-triazina
JP5388270B2 (ja) 2008-06-04 2014-01-15 株式会社Ａｄｅｋａ ２，４，６−トリス（ヒドロキシフェニル）−１，３，５−トリアジン化合物の製造方法
EP2138488A1 (en) 2008-06-26 2009-12-30 sanofi-aventis 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases
CN101747282A (zh) * 2008-12-10 2010-06-23 上海特化医药科技有限公司 一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途
AR077999A1 (es) 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
WO2011037610A1 (en) * 2009-09-23 2011-03-31 Albert Einstein College Of Medicine Of Yeshiva University Prostaglandin transporter inhibitors and uses thereof
WO2011048004A1 (en) 2009-10-23 2011-04-28 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin e2 synthase-1
US8586604B2 (en) 2010-08-20 2013-11-19 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin E2 synthase-1
AR086254A1 (es) 2011-05-26 2013-11-27 Lilly Co Eli Derivados de imidazol utiles para el tratamiento de artritis
FR2983859B1 (fr) * 2011-12-12 2014-01-17 Sanofi Sa Derives de 1,3,5-triazine-2-amine, leur preparation et leur application en diagnostique et en therapeutique
PE20142098A1 (es) * 2012-01-06 2015-01-08 Agios Pharmaceuticals Inc Compuestos terapeuticamente activos y sus metodos de uso
CA2873984A1 (en) 2012-05-23 2013-11-28 Stemergie Biotechnology Sa Inhibitors of the activity of complex (iii) of the mitochondrial electron transport chain and use thereof
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
JP2014031035A (ja) 2012-08-01 2014-02-20 Yamaha Motor Co Ltd 原動機付き鞍乗型車両
WO2015059618A1 (en) * 2013-10-22 2015-04-30 Glenmark Pharmaceuticals S.A. SUBSTITUTED PYRIMIDINE COMPOUNDS AS mPGES-1 INHIBITORS
TWI651310B (zh) * 2014-02-20 2019-02-21 日商日本煙草產業股份有限公司 三化合物及其醫藥用途
CN105586773A (zh) * 2014-11-13 2016-05-18 东丽纤维研究所（中国）有限公司 一种拒水抗紫外纺织品及其生产方法和用途
KR20180037270A (ko) 2015-08-17 2018-04-11 니뽄 다바코 산교 가부시키가이샤 히드록시트리아진 화합물 및 그의 의약 용도
EP3372589B1 (en) * 2015-10-29 2021-10-20 ASKA Pharmaceutical Co., Ltd. Pyrimidine derivative

Also Published As

Publication number Publication date
CA2936408A1 (en) 2015-08-27
US20230011968A1 (en) 2023-01-12
ES2704922T3 (es) 2019-03-20
IL247319B (en) 2019-11-28
US12398111B2 (en) 2025-08-26
RU2016137263A (ru) 2018-03-23
KR20160113727A (ko) 2016-09-30
RS58235B1 (sr) 2019-03-29
SMT201800684T1 (it) 2019-01-11
US20200087266A1 (en) 2020-03-19
AU2015219920B2 (en) 2018-12-20
JP2021054856A (ja) 2021-04-08
RU2016137263A3 (https=) 2018-10-04
SG11201606902QA (en) 2016-09-29
CA2936408C (en) 2022-09-13
ZA201606449B (en) 2017-11-29
DK3109240T3 (en) 2018-12-17
CN106232585B (zh) 2019-04-02
CL2016002091A1 (es) 2017-01-20
PH12016501651A1 (en) 2017-02-06
EP3456713A1 (en) 2019-03-20
JP2022120173A (ja) 2022-08-17
NZ721718A (en) 2021-08-27
JP2019065036A (ja) 2019-04-25
CY1121261T1 (el) 2020-05-29
TW201620881A (zh) 2016-06-16
AU2015219920A1 (en) 2016-07-14
SA516371701B1 (ar) 2019-01-21
MX369217B (es) 2019-10-31
HRP20182134T1 (hr) 2019-02-08
EP3109240B1 (en) 2018-10-24
TR201821158T4 (tr) 2019-01-21
SI3109240T1 (sl) 2019-02-28
BR112016018341B1 (pt) 2023-02-07
AR099498A1 (es) 2016-07-27
US20150266834A1 (en) 2015-09-24
PE20211548A1 (es) 2021-08-16
PH12016501651B1 (en) 2017-02-06
KR102360699B1 (ko) 2022-02-10
EP3109240A1 (en) 2016-12-28
CN106232585A (zh) 2016-12-14
EP3109240A4 (en) 2017-07-26
IL247319A0 (en) 2016-09-29
JP2015172039A (ja) 2015-10-01
RU2692789C2 (ru) 2019-06-27
PL3109240T3 (pl) 2019-03-29
PE20161236A1 (es) 2016-11-23
LT3109240T (lt) 2019-01-10
TWI651310B (zh) 2019-02-21
WO2015125842A1 (ja) 2015-08-27
JP6461637B2 (ja) 2019-01-30
PT3109240T (pt) 2019-01-21
BR112016018341A2 (https=) 2017-08-08
MX2016010875A (es) 2016-10-26

Similar Documents

Publication Publication Date Title
PH12016501651B1 (en) Triazine compound and use thereof for medical purposes
CA2925624C (en) Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
EA201991693A1 (ru) Производное пиридина в качестве ингибитора ask1 и способ его получения и применения
SG11201806930PA (en) Novel condensed pyrimidine compound or salt thereof
PH12016502168A1 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
MY192521A (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
EA201990833A1 (ru) Соединение пиридина
MX2017007814A (es) Compuesto de carbamoilpiridona policiclicos y su uso farmaceutico.
MY186126A (en) Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
MY194468A (en) Oxy-fluoropiperidine derivatives as kinase inhhiitor
WO2016089060A3 (en) Heterocyclic derivatives and use thereof
WO2019040106A3 (en) COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES
AU2018253590A1 (en) Imidazopyridazine compounds
PH12016502394A1 (en) 1, 3, 4-thiadiazole compounds and their use in treating cancer
NZ758449A (en) Heteroaromatic compounds useful in therapy
MX2015015168A (es) Derivados heterociclicos y sus usos.
MX2018002044A (es) Compuesto hidroxitriazina y su uso medico.
MY199237A (en) Methods of treating ocular conditions
WO2016004413A3 (en) Gls1 inhibitors for treating disease
MX380758B (es) Compuesto que tiene actividad inhibitoria de idh mutante, método de preparación y usos del mismo.
WO2019040105A3 (en) COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES
WO2014160143A3 (en) Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders
PH12016501645A1 (en) Aminopyrazolone derivative
EA201991208A1 (ru) Способы лечения множественного остеохондроматоза (мо)
WO2016089062A3 (en) Heterocyclic derivatives and use thereof